 At study entry Day 0, participants will be randomly assigned to one of two groups Arms A and B. Participants in both groups will receive standard of care SOC treatment for the flu, but those in Arm A will also receive one dose of IVIG and those in Arm B will receive a placebo for IVIG. Both IVIG and placebo will be given intravenously over at least 2 hours. 